{"organizations": [], "uuid": "7af5cca10daca92c14d53b85fe3165df6b054ad9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-feb-22-idUSL8N1QB5EH", "country": "US", "domain_rank": 408, "title": "Swiss stocks - Factors to watch on Feb 22", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.083, "site_type": "news", "published": "2018-02-22T14:16:00.000+02:00", "replies_count": 0, "uuid": "7af5cca10daca92c14d53b85fe3165df6b054ad9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-feb-22-idUSL8N1QB5EH", "ord_in_thread": 0, "title": "Swiss stocks - Factors to watch on Feb 22", "locations": [], "entities": {"persons": [], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "polyphor", "sentiment": "none"}, {"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "partners group", "sentiment": "none"}, {"name": "santhera pharmaceuticals", "sentiment": "none"}, {"name": "cembra money bank", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, Feb 22 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday:\nCOMPANY STATEMENTS * Cembra Money Bank said its net income rose 1 percent to 144.5 million Swiss francs in 2017. It proposed to increase its dividend to 3.55 francs per share.\n* Partners Group sait it raised a total of 3 billion euros for its latest direct private infrastructure offering.\n* Santhera Pharmaceuticals said it increased its share capital to pay the upfront consideration for the license to develop and commercialize a clinical stage candidate for pulmonary diseases obtained from Polyphor.\nECONOMY * Swiss industrial orders for Q4 are due at 0815 GMT.\nReporting by Zurich newsroom\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T14:16:00.000+02:00", "crawled": "2018-02-23T15:40:12.009+02:00", "highlightTitle": ""}